T-cells secreted equal amounts of IFNγ when used as effectors against either the tumor-RNA-pulsed dendritic cells derived from CCR2+HSCs, or KR158B tumor cells themselves (p = 0.5176), demonstrating that CCR2+HSCs-derived cells have the capacity to present antigen on their MHC. The gene discussed is HLA-C; the disease is neoplasm.